Southern Copper Corp vs Twist Bioscience Corp — how do they compare? Southern Copper Corp trades at $187.99 (market cap $146.07B), while Twist Bioscience Corp trades at $88.31 (market cap $5.45B). The key difference: Southern Copper Corp is far larger — about 26.8× Twist Bioscience Corp's market cap, and Southern Copper Corp pays a 2.28% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| SCCO | TWST | |
|---|---|---|
Market Cap | $146.07B | $5.45B |
Sector | Basic Materials | Health |
52-Week High | $218.85 | $102.88 |
52-Week Low | $90.54 | $24.16 |
Enterprise Value | $148.12B | $5.37B |
Dividend Yield | 2.28% | — |
Signals from Pluang's Aura AI — not financial advice
SCCO trades at $188.01, up 9.0% today, with a neutral technical signal and strong fundamentals including a 34.13% net income margin and robust cash flow. Recent earnings beats and positive news on copper demand from AI data centers highlight growth potential, though the stock trades above the consensus price target of $152.79.
Outlook is mixed: strong profitability and sector tailwinds support upside, but high valuation ratios and analyst caution pose risks. Investors should weigh earnings consistency against premium pricing and market volatility.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →